S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
BREAKING: The truth about war with China (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
BREAKING: The truth about war with China (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
BREAKING: The truth about war with China (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
BREAKING: The truth about war with China (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:APLM

Apollomics (APLM) Stock Forecast, Price & News

$3.34
-0.26 (-7.22%)
(As of 10/3/2023 ET)
Compare
Today's Range
$3.34
▼
$3.61
50-Day Range
$3.34
▼
$5.74
52-Week Range
$3.34
▼
$49.00
Volume
5,284 shs
Average Volume
87,671 shs
Market Capitalization
$289.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Apollomics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
409.0% Upside
$17.00 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Apollomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.62) to ($0.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

942nd out of 966 stocks

Pharmaceutical Preparations Industry

421st out of 433 stocks

See Top Rated MarketRank™ Stocks Here

APLM stock logo

About Apollomics (NASDAQ:APLM) Stock

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

APLM Price History

APLM Stock News Headlines

October 3, 2023 | markets.businessinsider.com
Buy Rating on Apollomics Based on Promising Future Prospects and High Potential of Vebreltinib in Cancer Treatment
October 2, 2023 | americanbankingnews.com
Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 19.5% in September
October 4, 2023 | Stansberry Research (Ad)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
September 28, 2023 | tmcnet.com
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
July 30, 2023 | finance.yahoo.com
APLM - Apollomics, Inc.
July 20, 2023 | finance.yahoo.com
Retail investors account for 44% of Apollomics, Inc.'s (NASDAQ:APLM) ownership, while private equity firms account for 21%
July 8, 2023 | fool.com
Apollomics (NASDAQ: APLM)
June 19, 2023 | finance.yahoo.com
Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq
October 4, 2023 | Stansberry Research (Ad)
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
June 19, 2023 | finance.yahoo.com
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
See More Headlines
Receive APLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

APLM Company Calendar

Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLM
CUSIP
N/A
CIK
1944885
Web
www.apollomicsinc.com
Phone
886-2-7713-7952
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.92
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.45 million
Price / Sales
199.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($33.37) per share
Price / Book
-0.10

Miscellaneous

Outstanding Shares
86,800,000
Free Float
N/A
Market Cap
$289.91 million
Optionable
Not Optionable
Beta
1.11
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Guo-Liang Yu Ph.D. (Age 60)
    Co-Founder, CEO & Exec. Chairman
  • Dr. Sanjeev Redkar MBA (Age 54)
    Ph.D., Co-Founder, Pres, CFO & Exec. Director
  • Dr. Lijuan Jane Wang Ph.D. (Age 59)
    Chief Scientific Officer & GM of China
  • Ms. Brianna MacDonald J.D.
    Sr. VP & Gen. Counsel
  • Dr. Kin-Hung Yu M.D. (Age 61)
    Chief Medical Officer
  • Dr. Chinglin Lai Ph.D.
    Sr. VP of Biostatistics & Data Management

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













APLM Stock - Frequently Asked Questions

Should I buy or sell Apollomics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLM shares.
View APLM analyst ratings or view top-rated stocks.

How have APLM shares performed in 2023?

Apollomics' stock was trading at $24.20 at the start of the year. Since then, APLM stock has decreased by 86.2% and is now trading at $3.34.
View the best growth stocks for 2023 here.

Are investors shorting Apollomics?

Apollomics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 3,300 shares, a decline of 19.5% from the August 31st total of 4,100 shares. Based on an average daily volume of 17,400 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
View Apollomics' Short Interest.

What ETF holds Apollomics' stock ?

Range Cancer Therapeutics ETF holds 26,270 shares of APLM stock, representing 1.45% of its portfolio.

What is Apollomics' stock symbol?

Apollomics trades on the NASDAQ under the ticker symbol "APLM."

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollomics' stock price today?

One share of APLM stock can currently be purchased for approximately $3.34.

How much money does Apollomics make?

Apollomics (NASDAQ:APLM) has a market capitalization of $289.91 million and generates $1.45 million in revenue each year.

How can I contact Apollomics?

Apollomics' mailing address is 5/F-4 NO. 89 SONGREN ROAD XINYI DISTRICT, TAIPEI CITY F5, 11073. The official website for the company is www.apollomicsinc.com. The company can be reached via phone at 886-2-7713-7952.

This page (NASDAQ:APLM) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -